Ra Pharmaceuticals (NASDAQ:RARX) had its target price increased by BMO Capital Markets in a report released on Tuesday morning.

A number of other equities analysts have also recently weighed in on RARX. Jefferies Group set a $25.00 price target on shares of Ra Pharmaceuticals and gave the stock a buy rating in a research report on Friday, August 25th. Zacks Investment Research raised shares of Ra Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, September 26th. Royal Bank Of Canada began coverage on shares of Ra Pharmaceuticals in a research report on Thursday, September 14th. They set an outperform rating and a $21.00 price target on the stock. Finally, Credit Suisse Group lifted their price target on shares of Ra Pharmaceuticals from $19.00 to $23.00 and gave the stock an outperform rating in a research report on Friday, November 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $23.20.

Shares of Ra Pharmaceuticals (NASDAQ RARX) traded down $0.95 during mid-day trading on Tuesday, reaching $7.97. 1,110,800 shares of the company’s stock were exchanged, compared to its average volume of 131,548. Ra Pharmaceuticals has a 1 year low of $7.86 and a 1 year high of $27.84.

Ra Pharmaceuticals (NASDAQ:RARX) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.06). equities research analysts predict that Ra Pharmaceuticals will post -2.46 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in RARX. Tekla Capital Management LLC bought a new stake in Ra Pharmaceuticals in the 2nd quarter valued at $7,418,000. Citadel Advisors LLC bought a new stake in Ra Pharmaceuticals in the 3rd quarter valued at $4,664,000. Numeric Investors LLC bought a new stake in Ra Pharmaceuticals in the 2nd quarter valued at $2,484,000. Nexthera Capital LP bought a new stake in Ra Pharmaceuticals in the 2nd quarter valued at $1,912,000. Finally, Sectoral Asset Management Inc lifted its position in Ra Pharmaceuticals by 55.6% in the 3rd quarter. Sectoral Asset Management Inc now owns 278,082 shares of the company’s stock valued at $4,060,000 after acquiring an additional 99,332 shares in the last quarter. 69.64% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Ra Pharmaceuticals (RARX) Given New $0.00 Price Target at BMO Capital Markets” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://theolympiareport.com/2017/12/06/ra-pharmaceuticals-rarx-given-new-0-00-price-target-at-bmo-capital-markets.html.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.